ASBMR Three Year Symposia

ASBMR 三年研讨会

• 批准号: 9321912
• 负责人: DOUGLAS P. KIEL
• 金额: $ 4万
• 依托单位: AMERICAN SOCIETY FOR BONE & MINERAL RES
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-08-01 至 2019-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9321912
• 关键词: Academia; Address; Affect; American; Animal Model; Area; Biological Markers; Biomechanics; Bone structure; Cartilage; Cartilage Diseases; Cells; Clinical; Clinical Research; Complex; Data; Degenerative polyarthritis; Diné Nation; Disease; Fracture; Functional disorder; Funding; Genomics; Goals; Government; Grant; Image; Incidence; Industry; Joints; Laboratories; Medical Societies; Metabolism; Methods; Minerals; Molecular Biology; Morbidity - disease rate; Musculoskeletal Diseases; Osteoporosis; Patient Care; Patients; Physiology; Professional Organizations; Recording of previous events; Research; Research Personnel; Scientific Societies; Scientist; Serum; Skeleton; Societies; State-of-the-Art Reviews; Surrogate Markers; Time; Translating; Underrepresented Minority; United States National Institutes of Health; Woman; base; bone; bone fragility; bone quality; burden of illness; clinical application; cost; disability burden; fracture risk; improved; in vivo; joint destruction; meetings; men; mortality; precision medicine; prevent; skeletal; skeletal disorder; symposium; translation to humans

The American Society for Bone and Mineral Research (ASBMR), the largest professional, scientific and medical society established to bring together clinical and laboratory-based scientists who are involved in the study of bone and mineral metabolism, has had a successful history of conducting annual topical meetings funded by single year NIH R13 grants since 2002. This application seeks funding for a three year R13 grant to advance the field of skeletal diseases by focusing on three specific areas of scientific research: 1) skeletal genomics (“Bone-omics–Translating Genomic Discoveries into Clinical Applications”); 2) bone fragility (“Current Concepts in Bone Fragility: From Cells to Surrogates”); 3) skeletal contributions to the pathophysiology and clinical manifestations of osteoarthritis (“Skeletal Contributions to Joint Degeneration and Osteoarthritis”). These three areas cover a range of topics that collectively contribute to a majority of the clinical morbidity and mortality of skeletal disease. The overall objective of this R13 is to stimulate further advances that will result in improved patient care for skeletal diseases by bringing together the best researchers for each of the three symposia that will be held in conjunction with the annual meetings of the ASBMR. Each of the three symposia will review the state of the art in each topic area, exchanging ideas with attendees, and stimulating the interaction between young and established researchers. For each of the three symposia, attendees will be encouraged to attend the subsequent ASBMR Annual Meetings for additional opportunities to interact with bone researchers. Agendas for all three years have been developed by an organizing committee with committed speakers for the first two years. The agendas include established and young investigators, men, women and underrepresented minority speakers. At the end of each meeting, a “dine-around” evening is planned to allow direct interaction between young investigators and more senior speakers at the meeting. In 2016, the symposium will appraise the latest contributions of the field of genomics to the understanding of skeletal disease mechanisms, ranging from basic molecular biology to animal models and bidirectional translation to humans, particularly within the scope of precision medicine and targeted treatments. The 2017 symposium will discuss the latest research on the mechanisms underlying skeletal fragility and state-of-the-art methods to assess fracture risk. In addition, new data supporting the use of surrogate markers for fracture will be discussed. The 2018 symposium will promote interaction among basic, translational and clinical researchers in skeletal and osteoarthritis research, with a focus on recent data emerging on cartilage-bone structure and physiology within articulating joints.

美国骨与矿物质研究协会（ASBMR）是美国最大的专业、科学和 医学协会成立，汇集临床和实验室为基础的科学家谁是参与 骨和矿物质代谢的研究，有成功的历史，举办年度专题会议 自2002年以来，由NIH R13赠款资助。该申请寻求三年R13赠款的资金， 通过专注于三个特定的科学研究领域来推进骨骼疾病领域：1）骨骼 基因组学（“骨组学-将基因组发现转化为临床应用”）; 2）骨脆性 （“骨脆弱性的当前概念：从细胞到替代品”）; 3）骨骼对骨脆弱性的贡献。 骨关节炎的病理生理学和临床表现（“Skeleton Contributions to Joint Degeneration and 骨关节炎”）。这三个领域涵盖了一系列主题，这些主题共同促成了 骨骼疾病的临床发病率和死亡率。R13的总体目标是进一步刺激 这些进步将通过汇集最好的技术， 将与联合国可持续发展大会年度会议同时举行的三次专题讨论会的研究人员 ASBMR。三个专题讨论会中的每一个都将审查每个主题领域的最新技术， 与会者，并刺激年轻和建立研究人员之间的互动。止三个 研讨会，与会者将被鼓励参加随后的ASBMR年会， 与骨骼研究人员互动的机会。所有三年的课程都是由一个 组委会与承诺发言人的头两年。议程包括既定的和 年轻的调查员，男性，女性和代表性不足的少数民族发言人。每次会议结束时， “聚餐”之夜计划让年轻的调查人员和更资深的调查人员之间直接互动 会上发言人。2016年，研讨会将评估基因组学领域的最新贡献 从基础分子生物学到动物模型， 以及对人类的双向翻译，特别是在精准医学和靶向治疗的范围内， 治疗。2017年研讨会将讨论骨骼肌相关机制的最新研究， 脆弱性和评估骨折风险的最先进方法。此外，支持使用 将讨论骨折的替代标记。2018年研讨会将促进基础， 骨骼和骨关节炎研究的转化和临床研究人员，重点关注最新数据 出现在关节内的软骨-骨结构和生理学上。